Clarient to Sell CombiMatrix's DNAarray Products | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – CombiMatrix today said that Clarient has licensed rights to commercialize its DNAarray product portfolio.

The tests are based on array comparative genomic hybridization, and according to CombiMatrix, can provide physicians with "a comprehensive genomic profile of solid cancer tumors and blood-based cancers," which can help guide treatment.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.